Next Article in Journal / Special Issue
Attitudes towards Social Networking and Sharing Behaviors among Consumers of Direct-to-Consumer Personal Genomics
Previous Article in Journal / Special Issue
A Method for Biomarker Directed Survival Prediction in Advanced Non-Small-Cell Lung Cancer Patients Treated with Carboplatin-Based Therapy
Open AccessArticle

Rapid Collection of Biospecimens by Automated Identification of Patients Eligible for Pharmacoepigenetic Studies

by Yan V. Sun 1,2,3,* and Robert L. Davis 3
1
Department of Epidemiology, Rollins School of Public Health, Emory University, Atlanta, GA 30322, USA
2
Department of Biomedical Informatics, School of Medicine, Emory University, Atlanta, GA 30322, USA
3
Center for Health Research, Kaiser Permanente Georgia, Atlanta, GA 30305, USA
*
Author to whom correspondence should be addressed.
J. Pers. Med. 2013, 3(4), 263-274; https://doi.org/10.3390/jpm3040263
Received: 30 May 2013 / Revised: 4 September 2013 / Accepted: 10 September 2013 / Published: 26 September 2013
(This article belongs to the Special Issue Feature Paper 2013)
Epigenetics plays an important role in regulating gene expression, and can be modified by environmental factors and physiological conditions. Studying epigenetics is a promising approach to potentially improving the diagnosis, prevention and treatment of human diseases, and to providing personalized medical care. However, the role of epigenetics in the development of diseases is not clear because epigenetic markers may be both mediators and outcomes of human diseases. It is particularly complicated to study pharmacoepigenetics, as medication use may modify the epigenetic profile. To address the challenges facing pharmacoepigenetic research of human diseases, we developed a novel design to rapidly identify, contact, and recruit participants and collect specimens for longitudinal studies of pharmacoepigenetics. Using data in real-time from electronic medical record systems, we can identify patients recently start on new medications and who also have a blood test. Prior to disposal of the leftover blood by the clinical laboratory, we are able to contact and recruit these patients, enabling us to use both their leftover baseline blood sample as well as leftover specimens at future tests. With treatment-naïve and follow-up specimens, this system is able to study both epigenetic markers associated with disease without treatment effect as well as treatment-related epigenetic changes. View Full-Text
Keywords: electronic medical record; epigenetics; DNA methylation; epigenome; pharmacogenomics; pharmacogenetics; pharmacoepigenomics; epigenetic epidemiology electronic medical record; epigenetics; DNA methylation; epigenome; pharmacogenomics; pharmacogenetics; pharmacoepigenomics; epigenetic epidemiology
Show Figures

Figure 1

MDPI and ACS Style

Sun, Y.V.; Davis, R.L. Rapid Collection of Biospecimens by Automated Identification of Patients Eligible for Pharmacoepigenetic Studies. J. Pers. Med. 2013, 3, 263-274.

Show more citation formats Show less citations formats

Article Access Map by Country/Region

1
Only visits after 24 November 2015 are recorded.
Back to TopTop